Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

REGENXBIO Inc. - Common Stock (NQ:RGNX)

6.550 +0.220 (+3.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
RegenXbio's Duchenne Gene Therapy Secures FDA Orphan Drug Tag
The FDA has granted Orphan Drug Designation to RegenXbio Inc's (NASDAQ: RGNX) RGX-202, potential one-time gene therapy for Duchenne muscular dystrophy (... 
Via Benzinga
Exposures Product Safety
70 Biggest Movers From Yesterday
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The... 
Via Benzinga
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... 
Via Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
Barron's Latest Picks And Pans: Alleghany, Blade Air Mobility, Gene Therapy Picks And More
This weekend's Barron's cover story examines the bubbles in cryptocurrency, meme stocks and non-fungible tokens. Other featured articles discuss the stocks powering 2021... 
Via Benzinga
REGENXBIO inc (RGNX) Q3 2021 Earnings Call Transcript
RGNX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
Earnings Outlook For Regenxbio
Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trial
Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic... 
Via Benzinga
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
44 Biggest Movers From Yesterday
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares climbed 101.9% to close at $31.50 on Monday after the company announced its phase 2 study of XEN1101 for the treatment of... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Progenity (NASDAQ:PROG) stock moved upwards by 18.43% to $2.12 during Monday's regular session. Trading volume for this security as of 12:30 EST is 91.5... 
Via Benzinga
30 Stocks Moving In Monday's Mid-Day Session
Gainers Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares jumped 71.1% to $26.69 after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all... 
Via Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Could AbbVie's New Collaboration Be a Blockbuster?
AbbVie recently announced a strategic partnership with Regenxbio for wet age-related macular degeneration and diabetic retinopathy treatment. 
Via The Motley Fool
Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal
The big drugmaker wants another near-term growth driver. 
Via The Motley Fool
Looking Into Regenxbio's Return On Capital Employed
Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.04 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 18.58%, resulting in a loss of $... 
Via Benzinga
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector. 
Via Talk Markets
Regenxbio Stock Catapults To 7-Month High On AbbVie's $1.75 Billion Bet On Gene Therapy
Regenxbio stock rocketed Monday after the company announced an AbbVie eye-disease deal. At one point, RGNX stock hit a seven-month high. 
Via Investor's Business Daily
72 Biggest Movers From Yesterday
Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead... 
Via Benzinga
Why Regenxbio Stock Is Way Up Today
American biopharmaceutical giant AbbVie wants access to Regenexbio's gene therapy for macular degeneration. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Itamar Medical (NASDAQ:ITMR) shares increased by 46.58% to $30.25 during Monday's regular session. Trading volume for Itamar Medical's stock is 2.6 million... 
Via Benzinga
45 Stocks Moving In Monday's Mid-Day Session
Gainers Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets. Itamar Medical Ltd. (NASDAQ: ITMR)... 
Via Benzinga
Why Regenxbio Shares Are Trading Higher Today
Regenxbio Inc (NASDAQ: RGNX) is trading significantly higher Monday after the company, and AbbVie Inc (NYSE: ABBV), announced an eye care collaboration. The companies will develop... 
Via Benzinga
AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration
AbbVie Inc (NYSE: ABBV) and Regenxbio Inc (NASDAQ: RGNX) have partnered to develop and commercialize RGX-314, potential one-time gene therapy for wet age... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Itamar Medical (NASDAQ:ITMR) shares moved upwards by 44.37% to $29.8 during Monday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.